The emergence of new immunotherapies as the first line of treatment for cancer, necessitates the development of clinically useful biomarkers to identify patients who will benefit.
Watch Now
Gene therapy has made tremendous strides over the past decade or so. The first approved drugs are on the market, and literally hundreds of trials are underway offering unprecedented hope to patients with rare, debilitating genetic disorders. Nevertheless, safety issues continue to swirl around the field as adverse events are reported in trials involving both lentivirus and AAV vectors. Pricing and manufacturing pose additional hurdles that could significantly challenge the field.
Watch Now
workcast
The past decade has witnessed an emergence of technologies from various disciplines that are providing unprecedented opportunities to formulate and answer new types of biological questions. In particular, single-molecule approaches are revolutionizing biological inquiries by providing previously unattainable data on elementary biological processes. Because biological molecules do not function in isolation in the cell, measurements need to be improved to better emulate in vivo conditions by studying more-complex systems with many components, and they need to be applied to the cellular levels and even tissue levels. This Cell Press webinar will discuss the latest advances in single molecule technologies, and the challenges and opportunities associated with their extension to very large scales and in interpreting the large and complex datasets.
Watch Now
Cell and gene therapies have ignited the imagination of researchers and continue to populate the pipeline of many biopharmaceutical companies. While these drug products have become an essential part of the clinical arsenal to treat a host of diseases, their complex nature often makes them difficult to produce. Biopharma manufacturers are constantly searching for innovative products and methodologies that will make production faster and safer while keeping overall costs down.
Watch Now